Skip to main content

Advertisement

SpringerLink
Log in

Treatment of dysimmune neuropathies

  • ENS TEACHING REVIEW
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

IVIg and PE are similarly effective in accelerating the recovery but there is still little evidence that they can reduce mortality or long-term disability. Recent reports on the association of intravenous methylprednisolone or interferon-β (IFN-β) to IVIg did not result in significant further improvement. In chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) steroids, PE, and IVIG are initially similarly effective. The short-term effect of PE and IVIg and the side effects associated with the long-term use of steroids have prompted the use of several IS, interferon and,more recently, the anti-CD20 monoclonal-antibody Rituximab, but their efficacy has still to be proved in controlled studies. The recent identification of multifocal motor neuropathy (MMN) was shortly followed by the finding of an effective therapy. Almost 80% of patients respond to IVIg whose effect needs to be maintained with periodic infusions for long periods of time, and tends to decrease after several years. Also in this condition a number of immune modulating agents have been used to reduce the frequency or improve the effectiveness of IVIg, but their efficacy has not been so far confirmed in randomized trials. Similar conclusions can be drawn for neuropathies associated with monoclonal gammopathies where only PE and IVIg have proved to be effective in controlled studies, while the promising initial results obtained with Rituximab in neuropathy associated IgM monoclonal gammopathy awaits confirmation from controlled trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27(Suppl):S21–S24

    Google Scholar 

  2. Azulay JP, Blin O, Pouget J, Boucraut J, Billé-Turc F, Carles G, Serratrice G (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies. Neurology 44:429–432

    Google Scholar 

  3. Azulay JP, Rihet P, Pouget J Cador F, Blin O, Boucraut J, Serratrice G (1997) Long-term follow-up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry 62:391–394

    Google Scholar 

  4. Bech E, Andersen H, Orntoft TF, Jakobsen J (1998) Association of IgM type anti-GM1 antibodies and muscle strength in chronic acquired demyelinating polyneuropathy. Ann Neurol 43:72–78

    Google Scholar 

  5. Benedetti L, Grandis M, Nobbio L, Beronio A, Ghiglione E, Manzino M, Primavera A, Mancardi G, Schenone (2004) Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 29:748–749

    Google Scholar 

  6. Biessels GJ, Franssen H, van den Berg LH, Gibson A, Kappelle LJ, Venables GS, Wokke JHJ (1997) Multifocal motor neuropathy. J Neurol 244:143–152

    Google Scholar 

  7. Blume G, Pestronk A, Goodnough LT (1995) Anti-MAG antibodies associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 45:1577–1580

    Google Scholar 

  8. Bouche P, Moulonguet A, Younes-Chennoufi AB, Adams D, Bauman N, Meininger V, Léger J-M, Said G (1995) Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 59:38–44

    Google Scholar 

  9. Brannagan TH, Pradhan A, Heiman-Patterson T, Winkelmann AC, Styler MJ, Topolsky DL, Crilley PA, Schwartzman RJ, Brodsky I, Gladstone DE (2002) High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 58:1856–1858

    Google Scholar 

  10. Carpo M, Cappellari A, Mora G, Pedotti R, Barbieri S, Scarlato G, Nobile-Orazio E (1998) Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 50:1480–1482

    Google Scholar 

  11. Carpo M, Pedotti R, Allaria S, Lolli F, Matà S, Cavaletti G, Protti A, Pomati S, Scarlato G, Nobile-Orazio E (1999) Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies. J Neurol Sci 168:78–84

    Google Scholar 

  12. Chaudhry V, Corse A, Cornblath DR, Kuncl RW, Drachman DB, Freimer ML, Miller RG, Griffin JW (1993) Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 33:237–242

    Google Scholar 

  13. Chaudhry V, Cornblath DR, Griffin JW, O’Brien R, Drachman DB (2001) Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56:94–96

    Google Scholar 

  14. Chin RL, Sherman WH, Sander HW, Hays AP, Latov N (2003) Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 210:19–21

    Google Scholar 

  15. Choudhary PP, Hughes RA (1995) Long term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med 88:493–502

    Google Scholar 

  16. Comi G, Roveri L, Swan A, Willison H, Bojar M, Illa I, Karageorgiou C, Nobile-Orazio E, van den Bergh P, Swan T, Hughes RAC and the Inflammatory Neuropathy Cause and Treatment (INCAT) group (2002) A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249:1370–1377

    Google Scholar 

  17. Creange A, Lerat H, Meyrignac C, Degos J-D, Gherardi RK, Cesaro P (1998) Treatment of Guillain-Barré syndrome with interferon-β. Lancet 352:368–369

    Google Scholar 

  18. Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueida S, Stein DP, Cupler E, Sekul EA, Otero C (1996) A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 40:792–795

    Google Scholar 

  19. Di Troia A, Carpo M, Meucci N Pellegrino C, Allaria S, Gemignani F, Marbini A, Mantegazza R, Sciolla R, Manfredini E, Scarlato G, Nobile-Orazio E (1999) Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J Neurol Sci 164:64–71

    Google Scholar 

  20. Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, Jacobs J (1994) Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 57:778–783

    Google Scholar 

  21. Dyck PJ, O’Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, Mokri B, Swift T, Low PA, Windebank AJ (1982) Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11:136–141

    Google Scholar 

  22. Dyck PJ, O’Brien P, Swanson C, Low P, Daube J (1985) Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 35:1173–1176

    Google Scholar 

  23. Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, Swanson C (1986) Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Eng J Med 314:461–465

    Google Scholar 

  24. Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Goselin S, Bourque P, Smith BE, Cratz KM, Karnes JL, Evans BA, Pineda AA, O’Brien PC, Kyle RA (1991) Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 325:1482–1486

    Google Scholar 

  25. Dyck PJ, Prineas J, Pollard J (1993) Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds) Peripheral Neuropathy, 3rd edn. WB Saunders, Philadelphia, pp 1498–1517

  26. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O’Brien PC (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845

    Google Scholar 

  27. ENMC 79th international workshop: Multifocal motor neuropathy (Workshop report) (2001). Neuromusc Dis 11:309–314

    Google Scholar 

  28. Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I (1997) Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 350:1747

    Google Scholar 

  29. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, Zochodne DW (1986) An acute axonal form of Guillain-Barré polyneuropathy. Brain 109:1115–1126

    Google Scholar 

  30. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE (2000) Multifocal motor neuropathy improved by IVIg. Randomized, double-blind, placebo-controlled, study. Neurology 55:1257–1262

    Google Scholar 

  31. Feldman EL, Bromberg MB, Albers JW, Pestronk A (1991) Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 30:397–401

    Google Scholar 

  32. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome (1987) Efficiency of plasma exchange in Guillain-Barré Syndrome: role of replacement fluids. Ann Neurol 22:753–761

    Google Scholar 

  33. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome (1992) Plasma exchange in Guillain-Barré Syndrome: one year follow-up. Ann Neurol 32:94–97

    Google Scholar 

  34. Ghosh A, Littlewood T, Donaghy M (2002) Cladribine in the treatment of IgM paraproteinemic polyneuropathy. Neurology 59:1290–1291

    Google Scholar 

  35. Good JL, Cherenama M, Mayer RF, Koski CL (1998) Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51:1735–1738

    Google Scholar 

  36. Gorson KC, Ropper AH (1997) Axonal neuropathy associated with monoclonal gammopathy of undetermined significance. J Neurol Neurosurg Psychiatry 63:163–168

    Google Scholar 

  37. Gorson KC, Amato AA, Ropper AH (2004) Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 63:715–717

    Google Scholar 

  38. Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao CY, Yang C, Tian M, Mishu B, Cornblath DR, McKahnn GM, Asbury AK (1995) Guillain-Barré syndrome in Northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 118:577–595

    Google Scholar 

  39. Guillain-Barré Syndrome Steroid Trial Group (1993) Double blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 341:586–590

    Google Scholar 

  40. Hadden RDM, Sharrack B, Bensa S, Soudain SE, Hughes RAC (1999) Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 53:57–61

    Google Scholar 

  41. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K,Vandervoort MK, Feasby TE (1996) Plasma exchange in chronic inflammatory demyelinating polyneuropathy.A double blind, sham-controlled, cross-over study. Brain 119:1055–1066

    Google Scholar 

  42. Hahn AF, Bolton CF, Zochodne D, Feasby TE (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double blind, placebo-controlled, cross-over study. Brain 119:1067–1077

    Google Scholar 

  43. Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G (1996) Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci 137:145–149

    Google Scholar 

  44. Hermosilla E, Lagueny A, Vital C, Vital A, Ferrer X, Steck A, Julien J (1996) Peripheral neuropathy associated with monoclonal IgG of undetermined significance: clinical, electrophysiologic, pathologic and therapeutic study of 14 cases. J Peripher Nerv Sys 1:139–148

    Google Scholar 

  45. Hughes RAC (2001) Chronic inflammatory demyelinating polyradiculoneuropathy (editorial). Ann Neurol 50:281–282

    Google Scholar 

  46. Hughes RAC, van der Meché FGA (1999) Corticosteroids for treating Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update Software

  47. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial of prednisolone in acute polyneuropathy. Lancet ii:750–753

    Google Scholar 

  48. Hughes RAC, Hadden RDM, Gregson NA, Smith KJ (1999) Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 100:74–97

    Google Scholar 

  49. Hughes RAC, Bensa S, Willison HJ, van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A and the Inflammatory Neuropathy Cause and Treatment (INCAT) group (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195–201

    Google Scholar 

  50. Hughes RAC, Raphael JC, Swan AV, van Doorn PA (2002) Intravenous immunoglobulin for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software

  51. Hughes RAC, Wijdicks EFM, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC (2003) Practice parameter: immunotherapy for Guillain-Barré syndrome. Report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 71:736–740

    Google Scholar 

  52. Hughes RAC, Swan AV, van Doorn PA (2004) Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). In: The Cochrane Library, Issue 3, Chichester, UK: John Wiley and Sons, Ltd

  53. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF (1993) Relapse in Guillain Barré syndrome after treatment with human immune globulin. Neurology 43:872–875

    Google Scholar 

  54. Knecht H, Baumberger M, Tobòn A, Steck A (2004) Sustained remission of CIDP associated with Evans syndrome. Neurology 63:730–732

    Google Scholar 

  55. Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M, Yuki N (2001) Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve 24:54–58

    Google Scholar 

  56. Léger J-M, Chassande B, Musset L, Meininger V, Bouche P, Bauman N (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind placebo-controlled study. Brain 124:145–153

    Google Scholar 

  57. Levine TD, Pestronk A (1999) IgM antibody related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 52:1701–1704

    Google Scholar 

  58. Lunn MPT, Nobile-Orazio E (2003) Immunotherapy for IgM anti-myelinassociated glycoprotein paraproteinassociated peripheral neuropathies (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software

  59. Magy L, Chassande B, Maisonobe T, Bouche P, Vallat JM, Leger JM, Brouet JC (2003) Polyneuropathy associated with IgG/A monoclonal gammopathy: a clinical and electrophysiological study of 15 patients. Eur J Neurol 10:677–685

    Google Scholar 

  60. Mariette X, Chastang C, Clavelou P, Louboutin J-P, Leger J-M, Brouet J-C, for the IgM-associated Polyneuropathy Study Group (1997) A randomised clinical trial comparing interferon-α and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 63:28–34

    Google Scholar 

  61. Mariette X, Brouet J-C, Chevret S, Leger J-M, Clavelou P, Pouget J, Vallat J-M, Vial C (2000) A randomised double blind trial versus placebo does not confirm the benefit of α-interferon in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 69:274–283

    Google Scholar 

  62. Martina ISJ, van Doorn PA, Schmitz PIM, Meulstee J, van der Meché FGA (1999) Chronic motor neuropathies: response to interferon-β1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry 66:197–201

    Google Scholar 

  63. McCombe PA, Pollard JD, McLeod JG (1987) Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 110:1617–1630

    Google Scholar 

  64. McCrone P, Chisholm D, Knapp M, Hughes RAC, Comi G, Dalakas M, Illa I, Kilindireas C, Nobile-Orazio E, Swan A, Van den Bergh P, Willison HJ, the INCAT Study Group (2003) Cost-Utility Analysis of Intravenous Immunoglobulin and Prednisolone for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Eur J Neurol 10:687–694

    Google Scholar 

  65. Mehndiratta MM, Hughes RAC (2002) Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). In: The Cochrane Library, Issue 4:2002. Oxford: Update Software

  66. Mehndiratta MM, Hughes RAC, Agarwal P (2004) Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley and Sons, Ltd

  67. Mehndiratta MM, Sen K, Tatke M, Bajaj BK (2004) IgA monoclonal gammopathy of undetermined significance with peripheral neuropathy. J Neurol Sci 221:99–104

    Google Scholar 

  68. Mendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, Pittman GL, Kyler RS, roelofs RI, Whitaker JN, Bertorini TE (1985) Plasma exchange and prednisone in Guillain-Barré syndrome: a controlled randomized trial. Neurology 35:1551–1555

    Google Scholar 

  69. Mendell JR, Barohn S, Freimer ML, Kissel JT, King W, Nagaraja HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ, and the Working Group on Peripheral Neuropathy (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56:445–449

    Google Scholar 

  70. Meucci N, Cappellari A, Barbieri S, Scarlato G,Nobile-Orazio E (1997) Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 63:765–769

    Google Scholar 

  71. Meucci N, Baldini L, Cappellari A, Di Troia A, Allaria S, Scarlato G, Nobile-Orazio E (1999) Anti-MAG antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy. Ann Neurol 46:119–122

    Google Scholar 

  72. Molenaar DSM, van Doorn PA, Vermeulen M (1997) Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 62:388–390

    Google Scholar 

  73. Mowzonn N, Sussman A, Bradley WG (2001) Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 185:119–122

    Google Scholar 

  74. Nemni R, Santuccio G, Calabrese E, Galardi G, Canal N (2003) Efficacy of cyclosporine treatment in multifocal motor neuropathy. J Neurol 250:1118–1120

    Google Scholar 

  75. Nobile-Orazio E (1998) Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ (eds) Immunological and infectious diseases of the peripheral nerves. Cambridge University Press, Cambridge, pp 169–189

  76. Nobile-Orazio E (2001) Multifocal motor neuropathy. J Neuroimmunol 115:4–18

    Google Scholar 

  77. Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G (1993) High dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 43:537–544

    Google Scholar 

  78. Nobile-Orazio E, Carpo M, Allaria S, Gamba M (1999) Diagnostic relevance of anti-neural antibodies in dysimmune neuropathies. Electroencephalogr Clin Neurophysiol Supplement 50:419–427

    Google Scholar 

  79. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G (2000) Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relation with immune therapies. Brain 123:710–717

    Google Scholar 

  80. Nobile-Orazio E, Casellato C, Di Troia A (2002) Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol (Paris) 158:979–987

    Google Scholar 

  81. Notermans NC, Lokhorst HM, Franssen H, Van der Graaf Y, Teunissen LL, Jennekens FGI, Van den Berg LH, Wokke JHJ (1996) Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 47:1227–1233

    Google Scholar 

  82. Oksenhendler E, Chevret S, Léger J-M, Louboutin J-P, Bussel A, Brouet J-C, for the IgM-associated Polyneuropathy Study Group (1995) Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg Psychiatry 59:243–247

    Google Scholar 

  83. Palace J, Newsom-Davis J, Lecky B and the Myasthenia Gravis Study Group (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50:1778–1783

    Google Scholar 

  84. Pestronk A, Cornblath DR, Ilyas A, Baba H, Quarles RH, Griffin JW, Alderson K, Adams RN (1988) A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 24:73–78

    Google Scholar 

  85. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. (2003) Treatment of IgM associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74:485–489

    Google Scholar 

  86. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349:225–230

    Google Scholar 

  87. Pritchard J, Gray IA, Idrissova ZR, Lecky BRF, Sutton IJ, Swan AV, Willison HJ, Winer JB, Hughes RAC (2003) A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology 61:1282–1284

    Google Scholar 

  88. Raphael J-C, Chevret S, Jars-Guincestre M-Ce for the French Guillain-Barré Syndrome Cooperative Group (2001). Intravenous immunoglobulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235–238

    Google Scholar 

  89. Raphael JC, Chevret S, Hughes RAC, Annane D (2002) Plasma exchange for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, Issue 4, Oxford: Update Software

  90. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwhol A, Steck AJ (2003) Rituximab in the treatment of anti-MAG associated polyneuropathy. Muscle Nerve 27:611–615

    Google Scholar 

  91. Rojas-Garcia R, Gallardo E, de Andrés I, de Luna N, Juarez J, Juarez C, Sànchez P, Illa I (2003) Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology 61:1814–1816

    Google Scholar 

  92. Ropper AH (1992) The Guillain-Barré syndrome. N Eng J Med 326:1130–1136

    Google Scholar 

  93. Ropper AH (1994) Miller Fisher Syndrome and other acute variants of Guillain-Barré syndrome. Baillière’s Clinical Neurology Vol 3, No. 1:95–106

  94. Ruegg SJ, Fuhr P, Steck AJ (2004) Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 63:2178–2179

    Google Scholar 

  95. Saperstein DS, Katz JS, Amato AA, Barohn RJ (2001) Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 24:311–324

    Google Scholar 

  96. Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile-Orazio E (2004) How-long is IVIg effective in multifocal motor neuropathy? Neurology 62:666–668

    Google Scholar 

  97. The Dutch Guillain-Barré Study Group (1994) Treatment of Guillain-Barré syndrome with high-dose immunoglobulins combined with methylprednisolone: a pilot study. Ann Neurol 35:749–752

    Google Scholar 

  98. The French Cooperative Group on Plasma exchange in Guillain-Barré Syndrome (1997) Appropriate number of plasma exchanges in Guillain- Barré Syndrome. Ann Neurol 41:298–306

    Google Scholar 

  99. The Guillain-Barré Syndrome Study Group (1985) Plasmapheresis and acute Guillain-Barré Syndrome. Neurology 35:1096–1104

    Google Scholar 

  100. Thompson N, Choudhary P, Hughes RAC, Quinlivan RM (1996) A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 243:280–285

    Google Scholar 

  101. Umapathi T, Hughes R (2002) Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 9:683–685

    Google Scholar 

  102. Umapathi T, Hughes RAC, Nobile-Orazio E, Leger JM (2002) Immunosuppressive treatment for multifocal motor neuropathy (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software

  103. Vallat J-M, Tabaraud F, Sindou P, Preux MD, Vandenberghe A, Steck A (2000) Myelin widenings and MGUSIgA: an immunoelectron microscopic study. Ann Neurol 47:808–811

    Google Scholar 

  104. Vallat J-M, Hahn AF, Leger J-M, Cros DP, Magy L, Tabaraud F, Bouche P, Preux P-M (2003) Interferon beta-1a as an investigational treatment for CIDP. Neurology 60(Suppl 3):S23–S28

    Google Scholar 

  105. Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, Jennekens FGI, Wokke JHJ (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59:248–252

    Google Scholar 

  106. Van den Berg LH, Franssen H, Wokke JHJ (1998) The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 121:421–428

    Google Scholar 

  107. Van den Berg-Vos RM, Franssen H, Wokke JHJ, Van Es HW, Van den Berg LH (2000) Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 48:919–926

    Google Scholar 

  108. Van den Berg-Vos RM, Van den Berg LH, Franssen H, Van Doorn PA, Merkies ISJ, Wokke JHJ (2000) Treatment of multifocal motor neuropathy with interferon-β1A. Neurology 54:1518–1521

    Google Scholar 

  109. Van den Berg-Vos RM, Franssen H, Wokke JHJ, Van den Berg LH (2002) Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 125:1875–1886

    Google Scholar 

  110. van der Meché FGA, Schmitz PIM and the Dutch Guillain-Barré Study Group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 326:1123–1129

    Google Scholar 

  111. Van Koningsveld R, Schmitz PI, Van der Meche FGA, Visser LH, Meulstee J, Van Doorn PA for the Dutch GBS study Group (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 363:192–196

    Google Scholar 

  112. van Schaik IN, Bossuyt PMM, Brand A, Vermeulen M (1995) Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta analysis. Neurology 45:1570–1577

    Google Scholar 

  113. Van Schaik IN, Winer JB, de Haan R, Vermeulen M (2002) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). In: The Cochrane Library, Issue 3:2002. Oxford: Update Software

  114. Vermeulen M, Van Oers MH (2002) Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 72:127–128

    Google Scholar 

  115. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo controlled study, J Neurol Neurosurg Psychiatry 56:36–39

    Google Scholar 

  116. Vucic S, Black KR, Chong PS, Cros D (2004) Multifocal motor neuropathy. Decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 63:1264–1269

    Google Scholar 

  117. Willison HJ, Yuki N (2002) Peripheral neuropathy and anti-glycolipid antibodies. Brain 125:2591–2625

    Google Scholar 

  118. Wilson H, Lunn MPT, Schey S, Hughes RAC (1999) Successful treatment of IgM paraproteinemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 66:575–580

    Google Scholar 

  119. Wollinsky KH, Hulser P-J, Brinkmeier H, Aulkemeyer P, Bossenecker W, Huber-Hartmann K-H, Rohrbach P, Schreiber H, Weber F, Kron M, Buchele G, Mehrkens H-H, Ludolph AC, Rudel R (2001) CSF filtration is an effective treatment of Guillain-Barré syndrome.A randomized clinical trial. Neurology 57:774–780

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurological Sciences Dino Ferrari Center, University of Milan IRCCS Humanitas Clinical Institute, Via Manzoni 56, 20089, Rozzano, Milan, Italy

    Eduardo Nobile-Orazio M. D., Ph. D.

Authors
  1. Eduardo Nobile-Orazio M. D., Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduardo Nobile-Orazio M. D., Ph. D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nobile-Orazio, E. Treatment of dysimmune neuropathies. J Neurol 252, 385–395 (2005). https://doi.org/10.1007/s00415-005-0805-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-005-0805-0

Key words

Search

Navigation